Brief: Curanex Pharmaceuticals Expands Drug Development Pipeline
02/04/2026 14:49
April 2 (Reuters) - Curanex Pharmaceuticals Inc CURX.O: CURANEX PHARMACEUTICALS INC - EXPANDS DRUG DEVELOPMENT PIPELINE - SEC FILING CURANEX PHARMACEUTICALS INC - TO FOCUS ON CANCER CACHEXIA AS NEW CORE INDICATION - SEC FILING Source text: [ID:n0001493152-26-014815] Further company coverage: CURX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Curanex Pharmaceuticals
See all newsBrief: Curanex Pharmaceuticals - Securities Class Action Filed Against Curanex Pharmaceuticals And Underwriters On July 23, 2026 - SEC Filing
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Curanex Pharmaceuticals Advancing Phyto-N Toward A Planned Investigational New Drug Submission To FDA For Ulcerative Colitis In Q4 2026